- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Annual Issues
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 757490, 9 pages
Targeted Resequencing Reveals ALK Fusions in Non-Small Cell Lung Carcinomas Detected by FISH, Immunohistochemistry, and Real-Time RT-PCR: A Comparison of Four Methods
1Department of Pathology, Haartman Institute, University of Helsinki, P.O. Box 21 (Haartmaninkatu 3), 00014 Helsinki, Finland
2Department of Pathology, HUSLAB, Helsinki University Central Hospital, P.O. Box 400, 00029 HUS, Finland
3Division of Pulmonary Medicine, Department of Medicine, University of Helsinki and Helsinki University Central Hospital, P.O. Box 340, 00029 HUS, Finland
4Lab21 Ltd, 184 Cambridge Science Park, Cambridge CB4 0GA, UK
5Technology Centre, Institute for Molecular Medicine Finland (FIMM), University of Helsinki, P.O. Box 20, 00014 Helsinki, Finland
Received 19 September 2012; Accepted 9 December 2012
Academic Editor: Akanchha Kesari
Copyright © 2013 Katja Tuononen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- R. Chiarle, C. Voena, C. Ambrogio, R. Piva, and G. Inghirami, “The anaplastic lymphoma kinase in the pathogenesis of cancer,” Nature Reviews Cancer, vol. 8, no. 1, pp. 11–23, 2008.
- M. Soda, Y. L. Choi, M. Enomoto et al., “Identification of the transforming EML4-ALK fusion gene in non-small cell lung cancer,” Nature, vol. 448, no. 7153, pp. 561–566, 2007.
- J. P. Koivunen, C. Mermel, K. Zejnullahu et al., “EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer,” Clinical Cancer Research, vol. 14, no. 13, pp. 4275–4283, 2008.
- U. McDermott, A. J. Iafrate, N. S. Gray et al., “Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors,” Cancer Research, vol. 68, no. 9, pp. 3389–3395, 2008.
- E. L. Kwak, Y. J. Bang, D. R. Camidge et al., “Anaplastic lymphoma kinase inhibition in non-small cell lung cancer,” The New England Journal of Medicine, vol. 363, no. 18, pp. 1693–1703, 2010.
- A. T. Shaw, B. Y. Yeap, B. J. Solomon et al., “Effect of crizotinib on overall survival in patients with advanced non-small cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis,” The Lancet Oncology, vol. 12, no. 11, pp. 1004–1012, 2011.
- K. Rikova, A. Guo, Q. Zeng et al., “Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer,” Cell, vol. 131, no. 6, pp. 1190–1203, 2007.
- K. Takeuchi, L. C. Young, Y. Togashi et al., “KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer,” Clinical Cancer Research, vol. 15, no. 9, pp. 3143–3149, 2009.
- Y. Togashi, M. Soda, S. Sakata et al., “KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only,” PLoS ONE, vol. 7, no. 2, Article ID e31323, 2012.
- C. Meldrum, M. A. Doyle, and R. W. Tothill, “Next-generation sequencing for cancer diagnostics: a practical perspective,” The Clinical Biochemist Reviews, vol. 32, no. 4, pp. 177–195, 2011.
- A. M. Sulonen, P. Ellonen, H. Almusa et al., “Comparison of solution-based exome capture methods for next generation sequencing,” Genome Biology, vol. 12, no. 9, p. R94, 2011.
- H. Li and R. Durbin, “Fast and accurate long-read alignment with Burrows-Wheeler transform,” Bioinformatics, vol. 26, no. 5, pp. 589–595, 2010.
- H. Li, B. Handsaker, A. Wysoker et al., “The sequence Alignment/Map format and SAMtools,” Bioinformatics, vol. 25, no. 16, pp. 2078–2079, 2009.
- K. Ye, M. H. Schulz, Q. Long, R. Apweiler, and Z. Ning, “Pindel: a pattern growth approach to detect break points of large deletions and medium sized insertions from paired-end short reads,” Bioinformatics, vol. 25, no. 21, pp. 2865–2871, 2009.
- M. Krzywinski, J. Schein, I. Birol et al., “Circos: an information aesthetic for comparative genomics,” Genome Research, vol. 19, no. 9, pp. 1639–1645, 2009.
- J. T. Robinson, H. Thorvaldsdóttir, W. Winckler et al., “Integrative genomics viewer,” Nature Biotechnology, vol. 29, no. 1, pp. 24–26, 2011.
- M. L. Wallander, K. B. Geiersbach, S. R. Tripp, and L. J. Layfield, “Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing,” Archives of Pathology & Laboratory Medicine, vol. 136, no. 7, pp. 796–803, 2012.
- P. A. Just, A. Cazes, A. Audebourg et al., “Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: a comprehensive study of Caucasian non-smokers,” Lung Cancer, vol. 76, no. 3, pp. 309–315, 2012.
- A. McLeer-Florin, D. Moro-Sibilot, A. Melis, D. Salameire, C. Lefebvre, F. Ceccaldi, et al., “Dual IHC and FISH testing for ALK gene rearrangement in lung adenocarcinomas in a routine practice: a french study,” Journal of Thoracic Oncology, vol. 7, no. 2, pp. 348–354, 2012.
- J. H. Paik, C. M. Choi, H. Kim et al., “Clinicopathologic implication of ALK rearrangement in surgically resected lung cancer: a proposal of diagnostic algorithm for ALK-rearranged adenocarcinoma,” Lung Cancer, vol. 76, no. 3, pp. 403–409, 2012.
- T. Sasaki, S. J. Rodig, L. R. Chirieac, and P. A. Jänne, “The biology and treatment of EML4-ALK non-small cell lung cancer,” European Journal of Cancer, vol. 46, no. 10, pp. 1773–1780, 2010.
- J. D. Rowley, “Chromosome translocations: dangerous liaisons revisited,” Nature Reviews Cancer, vol. 1, no. 3, pp. 245–250, 2001.
- M. Nambiar, V. Kari, and S. C. Raghavan, “Chromosomal translocations in cancer,” Biochimica et Biophysica Acta, vol. 1786, no. 2, pp. 139–152, 2008.
- S. Perner, P. L. Wagner, F. Demichelis et al., “EML4-ALK fusion lung cancer: a rare acquired event,” Neoplasia, vol. 10, no. 3, pp. 298–302, 2008.
- M. P. Martelli, G. Sozzi, L. Hernandez et al., “EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues,” American Journal of Pathology, vol. 174, no. 2, pp. 661–670, 2009.
- A. T. Shaw, B. Y. Yeap, M. Mino-Kenudson et al., “Clinical features and outcome of patients with non-small cell lung cancer who harbor EML4-ALK,” Journal of Clinical Oncology, vol. 27, no. 26, pp. 4247–4253, 2009.
- D. W. S. Wong, E. L. H. Leung, K. K. T. So et al., “The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS,” Cancer, vol. 115, no. 8, pp. 1723–1733, 2009.
- K. Inamura, K. Takeuchi, Y. Togashi et al., “EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset,” Modern Pathology, vol. 22, no. 4, pp. 508–515, 2009.
- X. Zhang, S. Zhang, X. Yang et al., “Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression,” Molecular Cancer, vol. 9, article 188, 2010.